Prognosis Research: A Strategic Initiative in Translational Pathways (PROGRESS)
Lead Research Organisation:
University College London
Department Name: Epidemiology and Public Health
Abstract
Strategic importance A basic form of clinical enquiry involves characterising people with disease or illness at one time point and following them up to see whether and why they have progressed at another time point. Such prognosis research is important in understanding how to ?translate? new approaches to improving health from initial discovery, through phases of evaluation and, where appropriate, into clinical practice. Prognosis research should complement and add value to MRC strategic aims, relating to: genetics, biomarkers, wellbeing, exploitation of health records and population based data and translational research.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines.
Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines.
Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.
Technical Summary
Strategic importance Prognosis research should be a basic science for translational research, clinical practice, personalised medicine and, with increasing periods of the lifecourse lived with chronic disease, for public health. Prognosis research should complement and add value to MRC strategic aims, principally those relating to: genetics, biomarkers, wellbeing, translational research and exploitation of health records and population based data.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. Internationally there have been no initiatives bringing together prognosis research across early and late stages in translation, across different prognosis research questions, and across disease areas. In short, the field is fragmented. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66m. With MRC support we will galvanise these resources with a Partnership across disease areas (cardiovascular, cancer, musculoskeletal, trauma and emergency medicine) and methodological disciplines (biostatistics, epidemiology, genetics, biomarkers, health services research).
Partnership workstreams The Partnership will break new ground in delivering three inter-related, milestone-driven workstreams: I Enabling and underpinning activities, through targeted workshops we will advance methods development in stratified medicine, ?transparency? standards in prognostic models, strategic direction across new and existing prognostic cohorts and knowledge transfer. II New research on translational exemplars involving new knowledge syntheses in stratified medicine (field synopses and high resolution systematic reviews), and new prospective analyses in our Partnership cohorts and trials. We will exploit novel opportunities in coronary disease (cohort with DNA and deep phenotyping n=5000); cancer (new translational DNA, plasma and tissue bioresource cohort of head and neck cancer patients, n=5000), acute severe haemorrhage trials in trauma (n=20,000), post-partum haemorrhage (n=15,000); musculoskeletal disorders n=7000 patients with repeat measures over 7 years. III boosting capability through training developing future national and international leaders in prognosis research through taught courses, PhD studentships, and Fellowships.
But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. Internationally there have been no initiatives bringing together prognosis research across early and late stages in translation, across different prognosis research questions, and across disease areas. In short, the field is fragmented. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.
Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.
Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66m. With MRC support we will galvanise these resources with a Partnership across disease areas (cardiovascular, cancer, musculoskeletal, trauma and emergency medicine) and methodological disciplines (biostatistics, epidemiology, genetics, biomarkers, health services research).
Partnership workstreams The Partnership will break new ground in delivering three inter-related, milestone-driven workstreams: I Enabling and underpinning activities, through targeted workshops we will advance methods development in stratified medicine, ?transparency? standards in prognostic models, strategic direction across new and existing prognostic cohorts and knowledge transfer. II New research on translational exemplars involving new knowledge syntheses in stratified medicine (field synopses and high resolution systematic reviews), and new prospective analyses in our Partnership cohorts and trials. We will exploit novel opportunities in coronary disease (cohort with DNA and deep phenotyping n=5000); cancer (new translational DNA, plasma and tissue bioresource cohort of head and neck cancer patients, n=5000), acute severe haemorrhage trials in trauma (n=20,000), post-partum haemorrhage (n=15,000); musculoskeletal disorders n=7000 patients with repeat measures over 7 years. III boosting capability through training developing future national and international leaders in prognosis research through taught courses, PhD studentships, and Fellowships.
Organisations
- University College London, United Kingdom (Collaboration, Lead Research Organisation)
- Servier Laboratories (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- Public Health England, Salisbury (Collaboration)
- UK Biobank, United Kingdom (Collaboration)
- National Institute for Health Research, United Kingdom (Collaboration)
- Farr Institute of Health Informatics Research (Collaboration)
- Akcea Therapeutics (Collaboration)
- NHS England, United Kingdom (Collaboration)
- London Sch of Hygiene and Trop Medicine, United Kingdom (Collaboration)
- University of York, United Kingdom (Collaboration)
- University of Birmingham, United Kingdom (Collaboration)
- Medical Research Council (Collaboration)
- Keele University, United Kingdom (Collaboration)
- British Heart Foundation (BHF) (Collaboration)
- Queen Mary, University of London, United Kingdom (Collaboration)
- AstraZeneca plc (Collaboration)
- UCL Partners, United Kingdom (Collaboration)
- Health Data Research Uk, London (Collaboration)
- European Commission, Belgium (Collaboration)
Publications

Asaria M
(2016)
Using electronic health records to predict costs and outcomes in stable coronary artery disease.
in Heart (British Cardiac Society)

Ball S
(2020)
Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK.
in Heart (British Cardiac Society)

Banerjee A
(2020)
92 aetiologic factors for heart failure: prevalence, co-occurrence, prognosis and potential for prevention in 170,885 incident HF cases
in European Heart Journal

Banerjee A
(2021)
'What is the risk to me from COVID-19?': Public involvement in providing mortality risk information for people with 'high-risk' conditions for COVID-19 (OurRisk.CoV).
in Clinical medicine (London, England)

Banerjee A
(2022)
A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential.
in European journal of heart failure

Bittar A
(2021)
Using General-purpose Sentiment Lexicons for Suicide Risk Assessment in Electronic Health Records: Corpus-Based Analysis.
in JMIR medical informatics

Blackburn R
(2018)
Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004-2015.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Burton CL
(2016)
Clinical Course and Prognostic Factors in Conservatively Managed Carpal Tunnel Syndrome: A Systematic Review.
in Archives of physical medicine and rehabilitation
Description | Estimating excess 1-year mortality associated with the COVID-19 |
Geographic Reach | National |
Policy Influence Type | Citation in other policy documents |
Impact | We provide policy makers, researchers, and the public a simple model and an online tool for understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as sustained efforts to target those at highest risk because of underlying conditions with a range of preventive interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality. |
Description | Excess cancer deaths in COVID-19 |
Geographic Reach | National |
Policy Influence Type | Citation in other policy documents |
Impact | Our work on excess cancer deaths in COVID-19 has been in the media continuously since March, now published in Lancet, and has been included in SAGE priorities and informed several policy changes including the early focus on 'indirect' deaths, the weekly reporting of excess deaths by the Office for National Statistics, and approaches to understanding vulnerable patients. A number of outlets featured the study outcomes including BBC Panorama's 'Britain's Cancer Crisis', the Independent's 'Cancer is the other 'big C' we can't afford to push aside' and Macmillian Cancer Support's 'The Forgotten 'C'? The impact of Covid-19 on cancer care'. https://www.bbc.co.uk/programmes/m000kqzv https://www.independent.co.uk/voices/coronavirus-nhs-cancer-testing-death-toll-illness-symptoms-check-gp-a9492161.html https://www.macmillan.org.uk/assets/forgotten-c-impact-of-covid-19-on-cancer-care.pdf |
Description | OurRisk.CoV risk calculator |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in other policy documents |
Impact | Our OurRisk.CoV risk calculator (available here: http://covid19-phenomics.org/PrototypeOurRiskCoV.html) has had 1.3 million pageviews from 636K users across the world (e.g. 21% of users from the United States). The risk calculator is also on the BHF website (https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/how-to-find-out-your-risk-when-it-comes-to-coronavirus) |
URL | https://covid19-phenomics.org/PrototypeOurRiskCoV.html |
Description | Accelerator Award |
Amount | £1,000,000 (GBP) |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
End | 03/2024 |
Description | Tackling multimorbidity at scale: Understanding disease clusters, determinants & biological pathways |
Amount | £2,900,000 (GBP) |
Funding ID | MR/V033867/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2021 |
End | 03/2024 |
Description | 4C Cost-effectiveness Collaboration |
Organisation | University of York |
Department | Centre for Health Economics (CHE) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Expertise in Clinical Epidemiology Grant writing Wriring of journal articles |
Collaborator Contribution | Health economics, evidence synthesis, decision modelling Grant writing Wriring of journal articles |
Impact | To follow |
Description | Akcea Therapeutics |
Organisation | Akcea Therapeutics |
Country | United States |
Sector | Private |
PI Contribution | TBC |
Collaborator Contribution | TBC |
Impact | Not yet. |
Start Year | 2018 |
Description | Astra Zeneca Cardiovascular Renal and Metabolic disorder (£0.5M) |
Organisation | AstraZeneca |
Department | Astra Zeneca |
Country | United States |
Sector | Private |
PI Contribution | As PI we will determine aetiologic relations among these commonly occurring conditions and the impact this may have on the design and interpretation of major trials. |
Collaborator Contribution | Collaboration between UCL and Astra Zeneca for a study on cardiovascular renal and metabolic disorders: 2019-2020, £0.5M |
Impact | Meetings and engagement activities have taken place to maximse scientific and societal benefits. |
Start Year | 2019 |
Description | British Heart Foundation-HDR UK National Cardiovascular Data Science Centre |
Organisation | British Heart Foundation (BHF) |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | As member of Scientific Steering Group gave invited talk at workshop (phenomics) and advised on priorities |
Collaborator Contribution | £10M |
Impact | Academic, research and clinical outputs |
Start Year | 2019 |
Description | Computing eInfrastructure for genomic and imaging data (eMEDLAB) |
Organisation | Medical Research Council (MRC) |
Department | MRC Medical Bioinformatics Infrastructure Grant |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Co-PI |
Collaborator Contribution | MRC £9M |
Impact | academic, research and clinical outputs |
Start Year | 2015 |
Description | Digital Innovation Hub DATA CAN |
Organisation | Health Data Research UK |
Country | United Kingdom |
Sector | Private |
PI Contribution | I contributed to the engagement of industry partners including IQVIA (2019-) |
Collaborator Contribution | IQVIA |
Impact | As part of the Digital Innovation Hub process I contributed to the engagement of industry partners including IQVIA |
Start Year | 2019 |
Description | European Innovative Medicines Initiative-2 Horizon 2020 Big Data for Better Outcomes BigData@Heart |
Organisation | European Commission |
Department | Horizon 2020 |
Country | European Union (EU) |
Sector | Public |
PI Contribution | I am the PI on this project and have provided scientific and management leadership |
Collaborator Contribution | ā¬9m H2020, ā¬9m Industry |
Impact | Academic and research outputs |
Start Year | 2017 |
Description | European leverage of health records and omics for drug development: Innovative Medicines Initiative 2 'Big Data for Better Outcomes' (Servier, Bayer, Novartis, Vifor, Actelion and Somalogic) |
Organisation | Servier Laboratories |
Country | France |
Sector | Private |
PI Contribution | I lead two work packages (informatics platform and omics enrichment) and sit on the five-member Executive of this 2017-2022 initiative seeking to tackle unmet need in heart failure, atrial fibrillation and acute coronary syndromes |
Collaborator Contribution | European leverage of health records and omics for drug development: Innovative Medicines Initiative 2 'Big Data for Better Outcomes' (£9m from Horizon 2020 + £9m in kind from Servier, Bayer, Novartis, Vifor, Actelion and Somalogic). |
Impact | TBC |
Start Year | 2017 |
Description | Farr Institute of Health Informatics Research |
Organisation | Farr Institute of Health Informatics Research |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research |
Collaborator Contribution | Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research |
Impact | None at present |
Start Year | 2013 |
Description | Farr Institute of Health Informatics Research |
Organisation | Farr Institute of Health Informatics Research |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research |
Collaborator Contribution | Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research |
Impact | None at present |
Start Year | 2013 |
Description | Farr Institute of Health Informatics Research |
Organisation | Farr Institute of Health Informatics Research |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research |
Collaborator Contribution | Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research |
Impact | None at present |
Start Year | 2013 |
Description | Farr Institute of Health Informatics Research, London |
Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Collaborator Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Impact | to follow |
Start Year | 2012 |
Description | Farr Institute of Health Informatics Research, London |
Organisation | Public Health England |
Country | United Kingdom |
Sector | Public |
PI Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Collaborator Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Impact | to follow |
Start Year | 2012 |
Description | Farr Institute of Health Informatics Research, London |
Organisation | Queen Mary University of London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Collaborator Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Impact | to follow |
Start Year | 2012 |
Description | Farr Institute of Health Informatics Research, London |
Organisation | UCL Partners |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Collaborator Contribution | Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development |
Impact | to follow |
Start Year | 2012 |
Description | Health Data Research UK |
Organisation | Health Data Research UK |
Country | United Kingdom |
Sector | Private |
PI Contribution | Inaugural Research Director |
Collaborator Contribution | £120m 2018-2023, with responsibility for London £10m |
Impact | Health Data Research in the UK |
Start Year | 2018 |
Description | HiGODS, Cross-cutting (Healthcare Informatics, Genomics/omics, Data Science) |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I have provided leadership contribution as Director, Healthcare Informatics, Genomics/omics, Data Science from 2016 |
Collaborator Contribution | tbc |
Impact | Meetings, Publications, Engagement Activities, Education, Policy, |
Start Year | 2016 |
Description | NIHR UCLH/UCL Biomedical Research Centre (Informatics) |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | I have been providing leadership vision and direction as the BRC Executive member since 2017 |
Collaborator Contribution | BRC £110m, £3m for theme 2017-2022 |
Impact | Publications, Meetings, Engagement Activities, Reports, Recommendation to policy |
Start Year | 2017 |
Description | OneLondon LHCRE |
Organisation | NHS England |
Country | United Kingdom |
Sector | Public |
PI Contribution | Academic and Research Leadership in bringing OnLondon LHCRE together with Luke Readman |
Collaborator Contribution | £0.9M |
Impact | Academic, research and clinical outputs |
Start Year | 2017 |
Description | PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k |
Organisation | Keele University |
Department | Research Institute for Primary Care and Health Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations. |
Collaborator Contribution | Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed. |
Impact | MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London) |
Start Year | 2011 |
Description | PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k |
Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
Department | Faculty of Epidemiology and Population Health |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations. |
Collaborator Contribution | Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed. |
Impact | MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London) |
Start Year | 2011 |
Description | PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k |
Organisation | Queen Mary University of London |
Department | Barts and The London School of Medicine and Dentistry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations. |
Collaborator Contribution | Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed. |
Impact | MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London) |
Start Year | 2011 |
Description | PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k |
Organisation | University College London |
Department | Research Department of Epidemiology and Public Health |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations. |
Collaborator Contribution | Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed. |
Impact | MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London) |
Start Year | 2011 |
Description | PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k |
Organisation | University of Birmingham |
Department | Department of Public Health, Epidemiology & Biostatistics (PHEB) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations. |
Collaborator Contribution | Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed. |
Impact | MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London) |
Start Year | 2011 |
Description | PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k |
Organisation | University of Oxford |
Department | Centre for Statistics in Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations. |
Collaborator Contribution | Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed. |
Impact | MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London) |
Start Year | 2011 |
Description | UCL Institute of Health Informatics |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Inaugural Director |
Collaborator Contribution | Current 5 year budget £33m |
Impact | Academic and Research |
Start Year | 2014 |
Description | UK BIobank |
Organisation | UK Biobank |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Cardiac outcomes working group |
Collaborator Contribution | Using research data to validate electronic health record data |
Impact | Papers in preparation |
Start Year | 2010 |
Description | Article on the daily mail on published research |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Daily mail newspaper report on research: "Weight gain risk is at its greatest from the ages of 18 to 34... and the chances of becoming obese DECREASE in middle, study suggests" |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.dailymail.co.uk/health/article-9953055/Weight-gain-risk-greatest-ages-18-34-study-sugges... |
Description | Multiple media mentions of excess cancer deaths in COVID-19 study |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Our work on excess cancer deaths in COVID-19 has been in the media continuously since March, now published in Lancet, and has been included in SAGE priorities and informed several policy changes including the early focus on 'indirect' deaths, the weekly reporting of excess deaths by the Office for National Statistics, and approaches to understanding vulnerable patients. A number of outlets featured the study outcomes including BBC Panorama's 'Britain's Cancer Crisis', the Independent's 'Cancer is the other 'big C' we can't afford to push aside' and Macmillian Cancer Support's 'The Forgotten 'C'? The impact of Covid-19 on cancer care'. https://www.bbc.co.uk/programmes/m000kqzv https://www.independent.co.uk/voices/coronavirus-nhs-cancer-testing-death-toll-illness-symptoms-check-gp-a9492161.html https://www.macmillan.org.uk/assets/forgotten-c-impact-of-covid-19-on-cancer-care.pdf |
Year(s) Of Engagement Activity | 2020 |
Description | OurRisk.CoV risk calculator |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Our OurRisk.CoV risk calculator (available here: http://covid19-phenomics.org/PrototypeOurRiskCoV.html) has had 1.3 million pageviews from 636K users across the world (e.g. 21% of users from the United States). The risk calculator is also on the BHF website (https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/how-to-find-out-your-risk-when-it-comes-to-coronavirus) |
Year(s) Of Engagement Activity | 2020 |
URL | https://covid19-phenomics.org/PrototypeOurRiskCoV.html |
Description | Talk given to HDR UK North and NICE Collaborative Workshop |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited to give talk titled ' A prognostic atlas for clinical practice guidelines' given to researchers, academics and other audience at the workshop. |
Year(s) Of Engagement Activity | 2021 |